[en] The administration of cyclosporin A (CyA) after autologous haematopoietic stem cell transplantation (HSCT) induces a systemic autoimmune syndrome mimicking graft-vs.-host disease (GVHD). This syndrome, termed autologous GVHD has notable anti-tumour activity in animal studies. We intended to induce autologous GVHD with CyA in patients undergoing an autologous HSCT. We prospectively studied 118 patients with miscellaneous malignancies undergoing an autologous HSCT with low-dose CyA to characterize the clinical syndrome, its frequency and clinical course, and to determine the factors affecting its incidence. Patients received CyA from d -1 through to d 28, first starting at 2 mg/kg intravenously and then orally as soon as feasible. The dose was adjusted to achieve pre-dose blood levels around 100 ng/ml. A skin biopsy was performed when a skin rash was observed. Thirty-three percent of the patients developed clinical GVHD: clinical stage 1 in 21 patients, stage 2 in seven patients, and stage 3 in three patients. Although total body irradiation (TBI) or high-dose cyclophosphamide were previously thought to be needed, autologous GVHD occurred in five out of 12 patients (42%) after a preparative regimen with high-dose melphalan alone. Autologous GVHD was significantly more frequent in patients older than 33 years, in patients who had received high doses of granulocyte-macrophage colony forming units (CFU-GM) and in those with a diagnosis of myeloid malignancy, compared with those with lymphoid malignancies or solid tumours. A significant negative association was also found with HLA-DR6. In lymphoma patients, GVHD occurred more frequently in advanced disease than in first or second complete remission (CR1-2) patients. All other factors studied were not predictive for GVHD. In conclusion, CyA-induced GVHD is reproducibly and safely induced with doses of CyA adapted to achieve blood levels around 100 ng/ml. In retrospective analysis, there was no survival advantage for patients with GVHD. Phase III trials with this approach are needed to evaluate its anti-tumoral effect.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Gothot, André ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Salmon, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Hermanne, J. P.
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
Antman K., Ayash L., Elias A., Wheeler C., Hunt M., Eder J.P., Teicher B.A., Critchlow J., Bibbo J., Schnipper L.E. (1992) A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal of Clinical Oncology 10:102-110.
Baron F., Beguin Y. (2000) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 40:468-476.
Bertz H., Burger J.A., Kunzmann R., Mertelsmann R., Finke J. (1997) Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect. Leukemia 11:281-283.
Bryson J.S., Jennings C.D., Caywood B.E., Kaplan A.M. (1989) Induction of a syngeneic graft-versus-host disease-like syndrome in DBA/2 mice. Transplantation 48:1042-1047.
Bryson J.S., Jennings C.D., Lowery D., Carlson S., Pflugh D., Caywood B., Kaplan A.M. (1999) Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease. Bone Marrow Transplantation 23:363-372.
Byrne J.L., Carter G.I., Ellis I., Haynes A.P., Russell N.H. (1997) Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplantation 20:517-520.
Carella A.M., Gaozza E., Congiu A., Carlier P., Nati S., Truini M., Viale M. (1991) Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Annals of Hematology 62:156-159.
Charak B.S., Sadowski R.M., Mazumder A. (1992) Antitumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma. Cancer Research 52:6482-6486.
Charak B.S., Agah R., Mazumder A. (1992) Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 80:179-184.
Eibl B., Schwaighofer H., Nachbaur D., Marth C., Gachter A., Knapp R., Bock G., Gassner C., Schiller L., Petersen F., Niederwieser D. (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508.
Gale R.P., Champlin R. (1984) How does bone-marrow transplantation cure leukaemia?. Lancet 2:28-30.
Geller R.B., Esa A.H., Beschorner W.E., Frondoza C.G., Santos G.W., Hess A.D. (1989) Successful in vitro graft-versus-tumor effect against an 1a-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74:1165-1171.
Giralt S., Weber D., Colome M., Dimopoulos M., Mehra R., Van Besien K., Gajewski J., Andersson B., Khouri I., Przepiorka D., Van Wolff B., Delasalle K., Korbling M., Seong D., Alexanian R., Champlin R. (1997) Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. Journal of Clinical Oncology 15:667-673.
Glazier A., Tutschka P.J., Farmer E.R., Santos G.W. (1983) Graft-versus-host disease in cyclosporine A-treated rats after syngeneic and autologous bone marrow reconstitution. Journal of Experimental Medicine 158:1-8.
Gruhn B., Häfer R., Kosmehl H., Fuchs D., Zintl F. (1998) Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood. Bone Marrow Transplantation 21:901-907.
Gryn J., Johnson E., Goldman N., Devereux L., Grana G., Hageboutros E., Fernandez E., Constantinou C., Harrer W., Viner E., Goldberg J. (1997) The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplantation 19:221-226.
Hermans-Le T., Paquet P., Pierard-Franchimont C., Arrese J.E., Pierard G.E. (1999) Regulatory function of factor XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. A hypothesis. Dermatology 198:184-186.
Hess A.D., Thoburn C. (1997) Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunological Reviews 157:111-123.
Hess A.D., Horwitz L.R., Beschorner W.E., Santos G.W. (1985) Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-1a specificity, including autoreactivity. Journal of Experimental Medicine 161:718-730.
Hess A.D., Fischer A.C., Horwitz L.R., Bright E.C., Laulis M.K. (1994) Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. Journal of Immunology 153:400-411.
Hood A.F., Vogelsang G.B., Black L.P., Farmer E.R., Santos G.W. (1987) Acute graft-versus-host disease: Development following autologous and syngeneic bone marrow transplantation. Archives of Dermatology 123:745-750.
Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562.
Johnson M.L., Farmer E.R. (1998) Graft-versus-host reactions in dermatology. Journal of the American Acadademy of Dermatology 38:369-392.
Jones R.J., Vogelsang G.B., Hess A.D., Farmer E.R., Mann R., Geller R.B., Piantadosi S., Santos G.W. (1989) Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1:754-757.
Kennedy M.J., Vogelsang G.B., Beveridge R.A., Farmer E.R., Altomonte V., Huelskamp A.M., Davidson N.E. (1993) Phase 1 trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. Journal of Clinical Oncology 11:478-484.
Kennedy M.J., Vogelsang G.B., Jones R.E., Farmer E.R., Hess A.D., Altomonte V., Huelskamp A.M., Davidson N.E. (1994) Phase 1 trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. Journal of Clinical Oncology 12:249-257.
Kersey J., Weisdorf D.J., Nesbit M.E., Lebien T., Woods W., McGlave P., Kim T., Vallera D., Goldman A., Bostrom B. (1987) Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New England Journal of Medicine 317:461-467.
Lerner K.G., Kao G.E., Storb R., Buckner C.D., Clift R.A., Thomas E.D. (1974) Histopathology of graft-versus-host reaction (GVHR) in human recipients of marrow from HLA-matched sibling donors. Transplantation Proceedings 6:367-371.
Martin P., Gooley T., Anasetti C., Petersdorf E., Hansen J. (1998) HLAs and risk of acute or chronic graft-vs.-host disease after marrow transplantation from HLA-identical sibling. Biology of Blood and Marrow Transplantation 4:128-133.
Noga S.J., Horwitz L.R., Kim H., Laulis M.K., Hess A.D. (1992) Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. Journal of Hematotherapy 1:75-84.
Pati A.R., Godder K., Abhyankar S.H., Gee A., Henslee-Downey P.J. (1996) Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplantation 17:1081-1083.
Pierard G.E., Nikkels-Tassoudji N., Arrese J.E., Nikkels A.F., Pierard-Franchimont C. (1998) L1-protein in incipient lymphocyte-depleted graft-versus-host disease: Expression in keratinocytes and coexpression with factor XIIIa in dermal cells. Turkian Journal of Dermatopathology 7:10-13.
Pierard G.E., Nikkels-Tassoudji N., Nikkels A.F., Arrese J.E., Jerusalem G., Beguin Y., Fillet G. (1998) Epidermal calprotectin expression in lymphocyte-depleted cutaneous graft-versus-host reaction. Archives of Argentinian Dermatology 48:139-142.
Pimpinelli N., Romagnoli P., Bosi A., Santucci M., Mori M., Guidi S., Giannotti B. (1993) Dendritic cells in the skin after allogeneic bone marrow transplantation: Immunohistochemical and electron microscopic monitoring. European Journal of Immunology 3:310-317.
Ramsay N.K., Kersey J., Robinson L., McGlave P., Woods W., Krivit W., Kim T.H., Goldman A., Nesbit M.E. (1982) A randomized study of the prevention of acute graft-versus-host disease. New England Journal of Medicine 306:392-397.
Talbot D.C., Powles R., Sloane J.P., Rose J., Treleaven J., Aboud H., Helenglass G., Parikh P., Smith C., Rowley M. (1990) Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia. Bone Marrow Transplantation 6:17-20.
Thien S.W., Goldman J.M., Galton D.G. (1981) Acute "graft-versus-host disease" after autografting for chronic granulocytic leukemia in transplantation. Annals of Internal Medicine 94:210-214.
Thomas E.D., Storb R., Clift R.A., Fefer A., Johnson F.L., Neiman P.E., Lerner K.G., Glucksberg H., Buckner C.D. (1975) Bonemarrow transplantation. New England Journal of Medicine 292:832-843.
Verdonck L.F., Lokhorst H.M., Dekker A.W., Nieuwenhuis H.K., Petersen E.J. (1996) Graft-versus-myeloma effect in two cases. Lancet 347:800-801.
Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., Storb R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. New England Journal of Medicine 300:1068-1073.
Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. (1981) Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. New England Journal of Medicine 304:1529-1533.
Yeager A.M., Vogelsang G.B., Jones R.E., Farmer E.R., Altomonte V., Hess A.D., Santos G.W. (1992) Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 79:3031-3035.
Yeager A.M., Vogelsang G.B., Jones R.E., Farmer E.R., Hess A.D., Santos G.W. (1993) Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leukemia & Lymphoma 11:215-220.
